Alexander Zverev, current Nr. 3 in ATP ranking, teams up with LUDI Therapeutics – Monaco’s biotech startup – to push the boundaries of medical innovation in sports-related injuries.
LUDI Therapeutics, a regenerative medicine biotech dedicated to the research and development of treatments for sports injuries, is thrilled to announce a new team member: Alexander “Sascha” Zverev. Alexander is the first athlete to join #TeamLudi, the platform created by LUDI Therapeutics for sportsmen and women to join forces and to make a profound and sustainable impact in the sport industry.
Alexander has been a permanent fixture in the top 10 since July 2017. Zverev’s career highlights include titles at the 2018 and the 2021 ATP Finals and 2020 Tokyo Olympics’ Gold Medal. He is the only active player outside of the Big Four with five ATP Masters 1000 titles. Zverev has won 19 ATP titles in singles and two in doubles.
LUDI Therapeutics, Monaco’s first women led biotech company which belongs to the pool of the global venture accelerator Monaco Foundry, secured its early-stage seed funding from Sport Horizon Holding, a specific fund in sports with involvement from Giorgio Chielini amongst other sport related profiles. This first investment was a testament of the continued need for innovation in sports. Currently, LUDI Therapeutics focuses on an unmet clinical need: the avoidance of long-term deficits in muscle architecture and function after a severe muscle injury, and is in the process of securing its Series A funding.
Worldwide, the regenerative medicine market is estimated to be $57B by 2027 and the sports injury market alone is more than $10B from professional to youth and beyond.
“As a professional athlete, injury prevention is one of the most important factors for a healthy and long-lasting career. That’s why I am really excited to join Ludi Therapeutics to make a positive impact in the careers of current and future athletes.”Alexander Zverev, new LUDI Therapeutics team member
Source: Ludi Therapeutics